{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:01:33Z","timestamp":1792317693887,"version":"4.4.0"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.metabol.2021.154918","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T07:47:01Z","timestamp":1635148021000},"page":"154918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"special_numbering":"C","title":["Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease"],"prefix":"10.1016","volume":"126","author":[{"given":"Hongyan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas S.","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinthe","family":"Boulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atit","family":"Dharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R.","family":"Lawler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z.I.","family":"Cherney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2021.154918_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.metabol.2021.154918_bb0010","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrneph.2012.281","article-title":"Improving the efficacy of RAAS blockade in patients with chronic kidney disease","volume":"9","author":"Lambers Heerspink","year":"2013","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1016\/j.metabol.2021.154918_bb0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.metabol.2021.154918_bb0020","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154918_bb0025","series-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","author":"Perkovic MJJ","year":"2019"},{"issue":"22","key":"10.1016\/j.metabol.2021.154918_bb0030","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.metabol.2021.154918_bb0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2018","journal-title":"N Engl J Med"},{"issue":"10166","key":"10.1016\/j.metabol.2021.154918_bb0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.metabol.2021.154918_bb0045","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.metabol.2021.154918_bb0050","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.metabol.2021.154918_bb0055","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.metabol.2021.154918_bb0060","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.metabol.2021.154918_bb0065","first-page":"531","article-title":"CCS\/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction","volume":"37","author":"McDonald","year":"2021","journal-title":"Can J Cardiol"},{"issue":"22","key":"10.1016\/j.metabol.2021.154918_bb0070","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.metabol.2021.154918_bb0075","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154918_bb0080","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.metabol.2021.154918_bb0085","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.metabol.2021.154918_bb0090","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.metabol.2021.154918_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8060779","article-title":"Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors","volume":"8","author":"Eickhoff","year":"2019","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.metabol.2021.154918_bb0100","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.metabol.2021.154918_bb0105","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamacardio.2017.1891","article-title":"The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure","volume":"2","author":"Verma","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.metabol.2021.154918_bb0110","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.2337\/dc20-2265","article-title":"Changes in cardiovascular biomarkers associated with the Sodium\u2013Glucose Cotransporter 2 (SGLT2) inhibitor ertugliflozin in patients with chronic kidney disease and type 2 diabetes","volume":"44","author":"Lawler","year":"2021","journal-title":"Diabetes Care"},{"issue":"Supplement 2","key":"10.1016\/j.metabol.2021.154918_bb0115","article-title":"SGLT2 inhibitors and the diabetic kidney","volume":"39","author":"Fioretto","year":"2016","journal-title":"Diabetes Care"},{"issue":"16","key":"10.1016\/j.metabol.2021.154918_bb0120","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/archinte.164.16.1737","article-title":"Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart","volume":"164","author":"Lim","year":"2004","journal-title":"Arch Intern Med"},{"issue":"8","key":"10.1016\/j.metabol.2021.154918_bb0125","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1681\/ASN.V1081778","article-title":"Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus","volume":"10","author":"Miller","year":"1999","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.metabol.2021.154918_bb0130","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00266.2007","article-title":"Activation of a local renin angiotensin system in podocytes by glucose","volume":"294","author":"Durvasula","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"issue":"11","key":"10.1016\/j.metabol.2021.154918_bb0135","first-page":"1456","article-title":"Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo","volume":"31","author":"Wingler","year":"2001"},{"issue":"1","key":"10.1016\/j.metabol.2021.154918_bb0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70454-8","article-title":"Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status","volume":"10","author":"Asensio Lopez","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.metabol.2021.154918_bb0145","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin\u2013angiotensin\u2013aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc"},{"key":"10.1016\/j.metabol.2021.154918_bb0150","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3389\/fendo.2018.00421","article-title":"The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity","volume":"9","author":"Wan","year":"2018","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1016\/j.metabol.2021.154918_bb0155","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1055\/s-0032-1331256","article-title":"Aberrant activation of the intrarenal renin-angiotensin system in the developing kidneys of type 2 diabetic rats","volume":"45","author":"Fan","year":"2013","journal-title":"Horm Metab Res"},{"issue":"7","key":"10.1016\/j.metabol.2021.154918_bb0160","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/jim-2017-000445","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes","volume":"65","author":"Yoshimoto","year":"2017","journal-title":"J Invest Med"},{"issue":"2","key":"10.1016\/j.metabol.2021.154918_bb0165","article-title":"An update on the tissue renin angiotensin system and its role in physiology and pathology","volume":"6","author":"Nehme","year":"2019","journal-title":"J Cardiovasc Dev Dis"},{"issue":"3","key":"10.1016\/j.metabol.2021.154918_bb0170","doi-asserted-by":"crossref","DOI":"10.1177\/1470320318803009","article-title":"Hyperglycemia activates the renin-angiotensin system and induces epithelial-mesenchymal transition in streptozotocin-induced diabetic kidneys","volume":"19","author":"Chen","year":"2018","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"10","key":"10.1016\/j.metabol.2021.154918_bb0175","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.metabol.2021.154918_bb0180","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.metabol.2021.154918_bb0185","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00232-001-0036-y","article-title":"Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat","volume":"182","author":"Vestri","year":"2001","journal-title":"J Membr Biol"},{"issue":"12","key":"10.1016\/j.metabol.2021.154918_bb0190","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1681\/ASN.V10122569","article-title":"Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption","volume":"10","author":"Vallon","year":"1999","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.metabol.2021.154918_bb0195","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.metabol.2021.154918_bb0200","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.metabol.2021.154918_bb0205","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/j.jcjd.2016.08.182","article-title":"The effect of SGLT2 inhibition on urinary adenosine excretion in patients with type 1 diabetes","volume":"40","author":"Rajasekeran","year":"2016","journal-title":"Can J Diabetes"},{"issue":"4","key":"10.1016\/j.metabol.2021.154918_bb0210","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","article-title":"Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging","volume":"140","author":"Kidokoro","year":"2019","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.metabol.2021.154918_bb0215","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.amjmed.2019.08.007","article-title":"Potential mechanisms of sodium-glucose co-transporter 2 inhibitor-related cardiovascular benefits","volume":"132","author":"Verma","year":"2019","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.metabol.2021.154918_bb0220","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jchf.2019.06.004","article-title":"Imaging, biomarker, and clinical predictors of cardiac remodeling in heart failure with reduced ejection fraction","volume":"7","author":"Aimo","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"6","key":"10.1016\/j.metabol.2021.154918_bb0225","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jacc.2017.06.016","article-title":"Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes","volume":"70","author":"Januzzi","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.metabol.2021.154918_bb0230","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12933-019-0938-6","article-title":"Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion","volume":"18","author":"Packer","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.metabol.2021.154918_bb0235","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","article-title":"Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure","volume":"17","author":"Soga","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.metabol.2021.154918_bb0240","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-018-0717-9","article-title":"Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes","volume":"17","author":"Matsutani","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"suppl_1","key":"10.1016\/j.metabol.2021.154918_bb0245","article-title":"Abstract 17041: effect of sodium-glucose cotransporter 2 inhibitor on vascular endothelial function and diastolic function in patients with heart failure with preserved ejection fraction (hfpef)","volume":"136","author":"Sakai","year":"2017"},{"issue":"12","key":"10.1016\/j.metabol.2021.154918_bb0250","doi-asserted-by":"crossref","DOI":"10.2337\/dc16-1312","article-title":"Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial?","volume":"39","author":"Verma","year":"2016","journal-title":"Diabetes Care"},{"issue":"21","key":"10.1016\/j.metabol.2021.154918_bb0255","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.metabol.2021.154918_bb0260","first-page":"1006","article-title":"Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: a cardiac magnetic resonance study","volume":"49","author":"Cohen","year":"2019"},{"issue":"17","key":"10.1016\/j.metabol.2021.154918_bb0265","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.metabol.2021.154918_bb0270","doi-asserted-by":"crossref","first-page":"178","DOI":"10.14740\/jocmr2857w","article-title":"A possible mechanism for renoprotective effect of sodium-glucose cotransporter 2 inhibitor: elevation of erythropoietin production","volume":"9","author":"Yanai","year":"2017","journal-title":"J Clin Med Res"},{"issue":"1","key":"10.1016\/j.metabol.2021.154918_bb0275","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jchf.2019.08.004","article-title":"Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes","volume":"8","author":"Li","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10.1016\/j.metabol.2021.154918_bb0280","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.metabol.2021.154918_bb0285","first-page":"632","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Trans Sci"},{"issue":"3","key":"10.1016\/j.metabol.2021.154918_bb0290","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3390\/ijms20030629","article-title":"Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system","volume":"20","author":"Ansary","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"17","key":"10.1016\/j.metabol.2021.154918_bb0295","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.metabol.2021.154918_bb0300","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-017-0654-z","article-title":"SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial","volume":"17","author":"Karg","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"10.1016\/j.metabol.2021.154918_bb0305","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1681\/ASN.2015060647","article-title":"Severity and frequency of proximal tubule injury determines renal prognosis","volume":"27","author":"Takaori","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.metabol.2021.154918_bb0310","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00277-005-1102-9","article-title":"Inappropriately low erythropoietin response for the degree of anemia in patients with noninsulin-dependent diabetes mellitus","volume":"85","author":"Symeonidis","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.metabol.2021.154918_bb0315","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fphys.2015.00167","article-title":"Renal erythropoietin-producing cells in health and disease","volume":"6","author":"Souma","year":"2015","journal-title":"Front Physiol"},{"issue":"12","key":"10.1016\/j.metabol.2021.154918_bb0320","doi-asserted-by":"crossref","first-page":"844","DOI":"10.14740\/jocmr2760w","article-title":"Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys","volume":"8","author":"Sano","year":"2016","journal-title":"J Clin Med Res"},{"issue":"3","key":"10.1016\/j.metabol.2021.154918_bb0325","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging role of SGLT-2 inhibitors for the treatment of obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.metabol.2021.154918_bb0330","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJMra063052","article-title":"The failing heart\u2014an engine out of fuel","volume":"356","author":"Neubauer","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.metabol.2021.154918_bb0335","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.metabol.2021.154918_bb0340","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cmet.2016.07.018","article-title":"Empagliflozin\u2019s fuel hypothesis: not so soon","volume":"24","author":"Lopaschuk","year":"2016","journal-title":"Cell Metab"},{"issue":"8","key":"10.1016\/j.metabol.2021.154918_bb0345","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.115.017355","article-title":"The failing heart relies on ketone bodies as a fuel","volume":"133","author":"Aubert","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.metabol.2021.154918_bb0350","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1172\/JCI115008","article-title":"Changes in citric acid cycle flux and anaplerosis antedate the functional decline in isolated rat hearts utilizing acetoacetate","volume":"87","author":"Russell","year":"1991","journal-title":"J Clin Investig"},{"issue":"7","key":"10.1016\/j.metabol.2021.154918_bb0355","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1080\/15548627.2015.1051295","article-title":"Autophagic adaptations in diabetic cardiomyopathy differ between type 1 and type 2 diabetes","volume":"11","author":"Kanamori","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.metabol.2021.154918_bb0360","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.biopha.2017.03.056","article-title":"The role of SIRT1 in diabetic cardiomyopathy","volume":"90","author":"Karbasforooshan","year":"2017","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.metabol.2021.154918_bb0365","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2337\/dci19-0074","article-title":"SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action","volume":"43","author":"Packer","year":"2020","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.metabol.2021.154918_bb0370","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.2337\/db16-0058","article-title":"The Na+\/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels","volume":"65","author":"Hawley","year":"2016","journal-title":"Diabetes."},{"issue":"1","key":"10.1016\/j.metabol.2021.154918_bb0375","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1038\/s41598-018-23420-4","article-title":"Canagliflozin inhibits interleukin-1beta-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms","volume":"8","author":"Mancini","year":"2018","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.metabol.2021.154918_bb0380","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1007\/s001250050822","article-title":"NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X","volume":"40","author":"Pickup","year":"1997","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2021.154918_bb0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/453892","article-title":"Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis","volume":"2010","author":"Kaneto","year":"2010","journal-title":"Mediators Inflamm"},{"issue":"9","key":"10.1016\/j.metabol.2021.154918_bb0390","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1172\/JCI120849","article-title":"Mitochondrial dysfunction in pathophysiology of heart failure","volume":"128","author":"Zhou","year":"2018","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.metabol.2021.154918_bb0395","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.metabol.2021.154918_bb0400","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia."},{"issue":"18","key":"10.1016\/j.metabol.2021.154918_bb0405","doi-asserted-by":"crossref","first-page":"429","DOI":"10.21037\/atm.2019.09.03","article-title":"The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus","volume":"7","author":"Leng","year":"2019","journal-title":"Ann Transl Med"},{"issue":"11","key":"10.1016\/j.metabol.2021.154918_bb0410","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8111814","article-title":"The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes","volume":"8","author":"Iannantuoni","year":"2019","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.metabol.2021.154918_bb0415","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.239","article-title":"Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice","volume":"4","author":"Hatanaka","year":"2016","journal-title":"Pharmacol Res Perspect"},{"issue":"6","key":"10.1016\/j.metabol.2021.154918_bb0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100777","article-title":"Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice","volume":"9","author":"Terami","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.metabol.2021.154918_bb0425","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/jdi.13009","article-title":"Canagliflozin, a sodium-glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats","volume":"10","author":"Kimura","year":"2019","journal-title":"J Diabetes Investig"},{"issue":"1","key":"10.1016\/j.metabol.2021.154918_bb0430","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","article-title":"Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study","volume":"16","author":"Solini","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.metabol.2021.154918_bb0435","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.dsx.2018.11.054","article-title":"Diabetic nephropathy: an update on pathogenesis and drug development","volume":"13","author":"A\/L B Vasanth Rao VR","year":"2019","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"issue":"3","key":"10.1016\/j.metabol.2021.154918_bb0440","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1681\/ASN.2011060628","article-title":"Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes","volume":"23","author":"Gohda","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.metabol.2021.154918_bb0445","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41591-019-0415-5","article-title":"A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes","volume":"25","author":"Niewczas","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2021.154918_bb0450","doi-asserted-by":"crossref","unstructured":"Dwijo Anargha Sindhughosa AGMKP. The involvement of proinflammatory cytokines in diabetic nephropathy: Focus on interleukin 1 (Il-1), interleukin 6 (Il-6), and tumor necrosis factor-alpha (TNF-\u0391) signaling mechanism.","DOI":"10.15562\/bmj.v6i1.299"},{"issue":"24","key":"10.1016\/j.metabol.2021.154918_bb0455","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.2174\/0929867322666150625095407","article-title":"Insights into the mechanisms involved in the expression and regulation of extracellular matrix proteins in diabetic nephropathy","volume":"22","author":"Hu","year":"2015","journal-title":"Curr Med Chem"},{"issue":"27","key":"10.1016\/j.metabol.2021.154918_bb0460","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/eurheartj\/ehu203","article-title":"Anti-inflammatory therapies for cardiovascular disease","volume":"35","author":"Ridker","year":"2014","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.metabol.2021.154918_bb0465","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/eurheartj\/ehaa099","article-title":"Targeting cardiovascular inflammation: next steps in clinical translation","volume":"42","author":"Lawler","year":"2020","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.metabol.2021.154918_bb0470","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11886-018-1067-7","article-title":"Tumor necrosis factor-\u03b1 in heart failure: an updated review","volume":"20","author":"Schumacher","year":"2018","journal-title":"Curr Cardiol Rep"},{"issue":"2","key":"10.1016\/j.metabol.2021.154918_bb0475","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"issue":"13","key":"10.1016\/j.metabol.2021.154918_bb0480","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","article-title":"SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice","volume":"292","author":"Wang","year":"2017","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.metabol.2021.154918_bb0485","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/dom.13301","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.metabol.2021.154918_bb0490","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/dom.13229","article-title":"Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis","volume":"20","author":"Packer","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2021.154918_bb0495","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes","volume":"85","author":"Garvey","year":"2018","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.metabol.2021.154918_bb0500","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.metabol.2021.154918_bb0505","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.metabol.2021.154918_bb0510","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.metabol.2021.154918_bb0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112394","article-title":"The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity","volume":"9","author":"Oelze","year":"2014","journal-title":"PLoS One"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049521002183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049521002183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:29:03Z","timestamp":1758428943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049521002183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":103,"alternative-id":["S0026049521002183"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154918","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154918","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154918"}}